DUBLIN – ADC Therapeutics SA added $76 million in a belated extension to its series E round, taking the total raise to $276 million. The initial close of $200 million was back in October 2017, but progress with its two lead antibody-drug conjugates (ADCs) prompted the latest injection of cash.